Bridgeway Capital Management LLC Has $796,000 Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Bridgeway Capital Management LLC decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 60.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 166,200 shares of the biopharmaceutical company’s stock after selling 253,287 shares during the period. Bridgeway Capital Management LLC owned approximately 0.29% of Vanda Pharmaceuticals worth $796,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of VNDA. Dimensional Fund Advisors LP boosted its stake in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock valued at $11,920,000 after buying an additional 227,428 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock worth $6,949,000 after acquiring an additional 24,483 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 4.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock valued at $3,925,000 after purchasing an additional 38,449 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Vanda Pharmaceuticals by 1.4% during the 4th quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company’s stock valued at $3,481,000 after purchasing an additional 9,840 shares during the last quarter. Finally, Northern Trust Corp increased its position in Vanda Pharmaceuticals by 1.3% during the 4th quarter. Northern Trust Corp now owns 507,442 shares of the biopharmaceutical company’s stock worth $2,431,000 after purchasing an additional 6,283 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders purchased 32,000 shares of company stock worth $151,180 over the last ninety days. 10.00% of the stock is owned by insiders.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $3.96 on Monday. Vanda Pharmaceuticals Inc. has a one year low of $3.85 and a one year high of $6.75. The company has a market cap of $233.38 million, a PE ratio of -12.38 and a beta of 0.69. The firm’s 50 day simple moving average is $4.52 and its 200 day simple moving average is $4.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. The company had revenue of $50.04 million for the quarter, compared to analysts’ expectations of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on VNDA shares. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.